Key Takeaways
- • Forbion raised €2.3 billion ($2.6 billion) across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII, lifting its assets under management to approximately €7.5 billion.
- • The two funds can finance around 30 portfolio companies, and their first investments have already been completed.
- • Dealroom presents the raise as evidence that institutional investors continue to back specialist life sciences managers with proven track records despite constrained biotech funding.
- • Forbion's 20-year record includes 142 financed companies, 37 of them created by Forbion, and portfolio companies that have delivered 21 approved medical products benefiting more than 1.6 million patients.
- • Other outlets describe the close as Europe's largest biotech venture fundraise, which is notable given that the continent accounts for only about 7% of global life sciences venture capital.
Summary
Forbion, a Netherlands-based biotech venture capital firm, has raised €2.3 billion ($2.6 billion) across two new funds, according to Dealroom. The capital was raised for Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The close lifts the firm's assets under management to approximately €7.5 billion. Dealroom frames the raise as a significant deployment of capital into a biotech market where funding remains limited.
The two funds are expected to finance around 30 portfolio companies, and their first investments have already been completed. Forbion Managing Partner and Co-Founder Sander Slootweg said the fundraise gives the firm substantial capacity to select, build and scale leading biotech companies at a time of limited capital availability. Other outlets describe the close as Europe's largest biotech venture fundraise, and note that the continent holds only about 7% of global life sciences venture capital.
Dealroom also highlights Forbion's 20-year track record. The firm has financed 142 companies, 37 of which Forbion created itself. Its portfolio companies have delivered 21 approved medical products that benefit more than 1.6 million patients globally. Dealroom presents the raise as evidence that major investors continue to support specialist managers with proven performance, even as the biotech financing environment becomes more difficult.
The two funds are expected to finance around 30 portfolio companies, and their first investments have already been completed. Forbion Managing Partner and Co-Founder Sander Slootweg said the fundraise gives the firm substantial capacity to select, build and scale leading biotech companies at a time of limited capital availability. Other outlets describe the close as Europe's largest biotech venture fundraise, and note that the continent holds only about 7% of global life sciences venture capital.
Dealroom also highlights Forbion's 20-year track record. The firm has financed 142 companies, 37 of which Forbion created itself. Its portfolio companies have delivered 21 approved medical products that benefit more than 1.6 million patients globally. Dealroom presents the raise as evidence that major investors continue to support specialist managers with proven performance, even as the biotech financing environment becomes more difficult.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.